Biocon
Search results
Concord Biotech Limited is a R&D driven biopharma Company that manufactures Active Pharmaceutical Ingredients (API) through fermentation & semi-synthetic process and finished formulations.
Concord Biotech Share Price: Find the latest news on Concord Biotech Stock Price. Get all the information on Concord Biotech with historic price charts for NSE / BSE.
Concord Biotech Limited is a R&D driven biopharma Company that manufactures Active Pharmaceutical Ingredients (API) through fermentation & semi-synthetic process and finished formulations.
Incorporated in 1984, Concord Biotech Limited is an India-based R&D-driven biopharma company and manufacturer of fermentation-based APIs across immunosuppressants and oncology.
Concord Biotech IPO bidding started from August 4, 2023 and ended on August 8, 2023. The allotment for Concord Biotech IPO was finalized on Friday, August 11, 2023. The shares got listed on BSE, NSE on August 18, 2023. Concord Biotech IPO price band is set at ₹705 to ₹741 per share.
Concord Biotech Limited (CBL) is an Indian biotechnology company headquartered in Ahmedabad. The company manufactures fermentation -based biopharmaceutical active pharmaceutical ingredients (APIs) sold worldwide.
Concord Biotech Limited is an R&D based Biotechnology company, having focus on the fermentation, semi-synthetic and synthesis based products. Since its inception in 2000, Concord has recorded...
Get the latest Concord Biotech Ltd (CONCORDBIO) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.
Aug 4, 2023 · Concord Biotech’s initial offering has opened for public subscription today, i.e, August 4, and will close on Tuesday, i.e., August 8. Price range: The bio-pharma company has set a price range at Rs 705-741 per share.
Aug 9, 2023 · Concord Biotech IPO Details. Concord Biotech IPO price band was at ₹ 705 to ₹ 741 per equity share. The company aims to raise ₹ 1,551 crore for the public issue which is completely an...
